HIV-1 capsid inhibitor (long-acting)
Lenacapavir
Brand names: Sunlenca
Adult dose
Dose: Initiation: 600mg PO days 1–2, 300mg PO day 8, then 927mg SC every 6 months
Route: SC/PO
Frequency: every 6 months (after loading)
Clinical pearls
- Heavily treatment-experienced multidrug-resistant HIV-1
- Twice-yearly SC dosing — major adherence advantage
Contraindications
- Concurrent strong CYP3A4 inducers (rifampicin, carbamazepine, phenytoin, St John's wort)
Side effects
- Injection site reactions (nodule, induration)
- Nausea
Interactions
- Strong CYP3A4 modulators
- Rifabutin
Monitoring
- Viral load
- CD4
Reference: BNF; NICE TA942; BHIVA; SmPC; https://bnf.nice.org.uk/drugs/lenacapavir/. Verify against your local formulary and the latest BNF before prescribing.
Related
Curated clinical cross-links plus same-class fallbacks.
Calculators
- Corrected QT Interval (Bazett) · ECG
- Bazett Corrected QT Interval (QTc) Calculator · Arrhythmia
- SMART Risk Score for Recurrent CVD · Cardiovascular Risk
- Long QT Syndrome (Schwartz Score) · Channelopathy / Sudden Cardiac Death
- PCSK9 Inhibitor Eligibility Assessment · Lipid Management
- Immune-Related Adverse Events (irAE) -- GI Toxicity Colitis Grading · Oncology-Related GI